/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway
HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway

Research To Practice | Oncology Videos · Aug 24, 2026

Experts review new data on PI3K/AKT/mTOR inhibitors in HR+ MBC, including the approval of getatolisib and strategies for managing toxicity.

San Antonio Breast Cancer Symposium's Agility Accelerates Data Dissemination and FDA Approvals

Unlike other major conferences, the San Antonio Breast Cancer Symposium (SABCS) has a unique ability to incorporate practice-changing data released just days before the event. This rapid presentation gets crucial information to clinicians, regulatory bodies like the FDA, and patients nearly six months faster than waiting for the next major meeting, speeding up drug review and approval processes.

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway thumbnail

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway

Research To Practice | Oncology Videos·3 months ago

For ESR1/PIK3CA Double Mutations, Disease Burden Dictates Therapy Choice Over Mutation Profile

When a patient has both ESR1 and PIK3CA pathway mutations, the choice between an oral SERD and a PI3K/AKT inhibitor is not straightforward. For patients with a low tumor burden and endocrine-sensitive disease, a better-tolerated single-agent oral SERD is preferred. For those with a higher disease burden, the more aggressive combination therapy is warranted.

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway thumbnail

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway

Research To Practice | Oncology Videos·3 months ago

Patient Ethnicity and Geography Critically Impact PI3K Inhibitor Tolerability

Clinical experience reveals significant geographic and ethnic variations in drug tolerability that are not always captured in global trials. For example, Asian patients often experience severe stomatitis with everolimus, while Hispanic patients in San Antonio with high rates of prediabetes face greater challenges with hyperglycemia from PI3K/AKT inhibitors, requiring different management strategies.

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway thumbnail

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway

Research To Practice | Oncology Videos·3 months ago

Proactive Antihistamines Started a Day Prior Mitigate Capivasertib-Induced Rash

To manage the common rash associated with the AKT inhibitor capivasertib, clinicians should prescribe non-sedating antihistamines twice daily. Crucially, patients should begin taking the antihistamine the day *before* starting capivasertib and continue for at least four weeks. This preemptive approach significantly reduces the incidence and severity of the rash.

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway thumbnail

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway

Research To Practice | Oncology Videos·3 months ago

PI3K Inhibitors Cause Hyperglycemia by Blocking Cellular Glucose Uptake, Rendering Insulin Ineffective

The hyperglycemia caused by PI3K inhibitors is a direct on-target effect. These drugs inhibit the PI3K pathway, which is the same pathway insulin uses to signal glucose to enter cells. This mechanistic understanding explains why giving insulin is ineffective for managing this side effect. Instead, oral agents like metformin or GLP-1s are required.

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway thumbnail

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway

Research To Practice | Oncology Videos·3 months ago

Duration on First-Line CDK4/6 Inhibitors Dictates Second-Line Treatment Strategy

A key heuristic for deciding between second-line endocrine therapy versus chemotherapy/ADC is the duration of benefit from the first-line CDK4/6 inhibitor. Patients who progress after a long duration (e.g., >18 months) are likely still endocrine-sensitive and should receive further endocrine-based therapy. Rapid progression (e.g., <6 months) suggests endocrine resistance, warranting a potential switch in modality.

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway thumbnail

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway

Research To Practice | Oncology Videos·3 months ago

Oncologists Should Stagger Triplet Therapy Initiation to Isolate Drug-Specific Toxicities

Instead of starting all three drugs in a triplet combination simultaneously, a more effective clinical approach is to introduce them sequentially. By starting one drug, then adding the second, and finally the third over a period of weeks or months, clinicians can more easily identify the source of any toxicities, leading to better management and improved patient compliance.

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway thumbnail

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway

Research To Practice | Oncology Videos·3 months ago

Oncologists Face a New Challenge: Treating Relapse After Adjuvant CDK4/6 Inhibitor Therapy

As CDK4/6 inhibitors move into the adjuvant setting, a new, unstudied patient population is emerging: those who relapse after receiving this combination early. Current metastatic trial data does not apply to these patients, creating a clinical evidence gap and forcing oncologists to extrapolate treatment decisions until new, dedicated studies are completed.

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway thumbnail

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway

Research To Practice | Oncology Videos·3 months ago